Melanoma-associated antigen A10 peptide presented by Human Leukocyte Antigen A*0201 (MAGE-A10/HLA-A*0201)

Melanoma-associated antigen A10 (MAGE-A10) peptide presented by Human Leukocyte Antigen A*0201 (HLA-A*0201) is a peptide-major histocompatibility complex (pMHC) that serves as a highly specific target for cancer immunotherapy [1, 6]. MAGE-A10 is a member of the cancer-testis antigen (CTA) family, which is typically expressed only in immune-privileged germ cells of the testes and placenta but is aberrantly upregulated in various malignancies, including non-small cell lung cancer, melanoma, and urothelial carcinoma [1, 9]. The specific nonameric peptide GLYDGMEHL (residues 254-262) is processed and presented on the cell surface by the HLA-A*02:01 allele, a common MHC class I molecule [2, 4]. This complex is recognized by the T-cell receptors (TCRs) of cytotoxic CD8+ T cells, making it a focal point for the development of adoptive cell therapies, such as Adaptimmune's ADP-A2M10 SPEAR T-cells [1, 8]. Therapeutic strategies targeting this complex aim to induce a potent and selective immune response against tumor cells while sparing healthy tissues that do not express MHC class I or the MAGE-A10 antigen [12, 15]. However, challenges include potential cross-reactivity with other MAGE family members and the risk of immune-related adverse events like cytokine release syndrome [10, 15].

Other names

MAGE-A10/HLA-A*02:01 complexMAGE-A10(254-262)/HLA-A*02:01GLYDGMEHL/HLA-A*02:01MAGE-A10 peptide presented by HLA-A*0201Melanoma-associated antigen A10 peptide presented by HLA-A*0201

Engineered T-cell receptor (TCR) binding to the peptide-MHC complex, leading to cytotoxic T-lymphocyte activation and tumor cell lysis [2, 4].